Developer docs
API playgroundTry for free, no card

Search company profiles

Cellectar Biosciences

Full company profile

uuid0000bbl

Namestring
Cellectar Biosciences
Legal namestring
Cellectar Biosciences, Inc.
Websiteurl
cellectar.com
Company typeenum
Public
Founded yearint
2002
Descriptiontext

Cellectar Biosciences, Inc. (NASDAQ: CLRB) is a late-stage clinical biopharmaceutical company founded in 2002 and headquartered in Florham Park, New Jersey, that develops targeted radiopharmaceutical cancer therapies using its proprietary Phospholipid Drug Conjugate (PDC) platform. The PDC platform exploits lipid raft microdomains in tumor cell plasma membranes to selectively deliver radioisotope and cytotoxic payloads to cancer cells while sparing healthy tissue, and supports multiple emission modalities — beta (I-131), Auger (I-125), and alpha (Ac-225) — from a single targeting chassis.

The company's lead product candidate is Iopofosine I 131 (CLR 131), a first-in-class PDC delivering iodine-131, which is advancing toward an FDA accelerated approval filing in relapsed/refractory Waldenström Macroglobulinemia (WM). Updated 12-month Phase 2b CLOVER WaM data showed an 83.6% overall response rate and 61.8% major response rate in WM patients. Iopofosine has accumulated Breakthrough Therapy, six Orphan Drug, two Fast Track, and four Rare Pediatric Disease designations from the FDA, plus EMA PRIME and Orphan Drug designations and Conditional Marketing Authorization feedback for the EU. The pipeline additionally includes CLR 125 (Auger-emitting, Phase 1b in triple-negative breast cancer) and CLR 225 (alpha-emitting actinium-225 program with preclinical activity in pancreatic and other solid tumors), both leveraging the same PDC delivery chassis.

Cellectar is pre-revenue with no commercialized products. Its business model depends on securing regulatory approval and then distributing iopofosine directly to hospitals and cancer treatment centers with radiopharmacy capabilities, supplemented today by NCI/NIH grant funding and recurring equity financings. The most recent capital event is the May 2026 oversubscribed financing of up to $140 million led by Nantahala Capital, intended to fund a confirmatory Phase 3 study in WM and an FDA accelerated approval filing. As of March 31, 2026, the company held approximately $8.3 million in cash and reported an accumulated deficit of $274.9 million as of December 31, 2025, with operating losses reflecting ongoing clinical development rather than commercial activity.

Short descriptiontext

Cellectar Biosciences is a late-stage clinical biopharmaceutical company developing targeted radiopharmaceutical cancer therapies using its proprietary Phospholipid Drug Conjugate (PDC) platform, with lead asset Iopofosine I 131 advancing toward FDA accelerated approval in Waldenström Macroglobulinemia.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersFlorham Park, United States
HQ citystring
Florham Park
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
targeted cancer therapy, phospholipid drug conjugates, radiopharmaceutical oncology, hematologic cancer treatment, clinical stage biopharmaceuticals
Industry2 codes
PRIMARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAC
Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Targeted Radiopharmaceutical Cancer Therapies
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales (Future)
TypeOne Time License
Description

Once regulatory approvals are obtained, the company plans to generate revenue through direct sales of iopofosine I 131 and future PDC-based therapeutics to hospitals, cancer treatment centers, and specialty pharmacies. Revenue model will involve specialty pharmaceutical distribution with hospital/health system contracting.

Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Cellectar Biosciences is a late-stage clinical biopharmaceutical company developing targeted radiopharmaceutical cancer therapies built on its proprietary Phospholipid Drug Conjugate (PDC) platform. Its lead clinical asset, Iopofosine I 131, delivers iodine-131 selectively to cancer cells via lipid raft targeting, with ongoing Phase 2b/Phase 3 programs in Waldenström Macroglobulinemia, multiple myeloma, CNS lymphoma, and pediatric high-grade glioma, plus earlier-stage Auger- and alpha-emitting PDC candidates for solid tumors.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Objective response rate data from CLOVER trial pending completion
+1 more record
Product overview1 text field

Cellectar Biosciences is a late-stage clinical biopharmaceutical company developing a portfolio of targeted cancer therapies using its proprietary Phospholipid Drug Conjugate (PDC) platform. The company's lead product is Iopofosine I 131, a first-in-class beta-emitting radioconjugate for treating relapsed or refractory Waldenström Macroglobulinemia and other hematologic cancers. The pipeline includes CLR 125 (iodine-125 Auger-emitting program for solid tumors) and CLR 225 (actinium-225 alpha-emitting program), both leveraging the PDC platform to selectively deliver radioisotopes to cancer cells while minimizing off-target effects.

Product and service3 records
1Iopofosine I 131 (CLR 131)
CategoryTargeted Radiopharmaceutical Therapy
Description

First-in-class Phospholipid Drug Conjugate delivering iodine-131 radioisotope selectively to cancer cells via lipid raft targeting; in development for relapsed/refractory Waldenström Macroglobulinemia, multiple myeloma, CNS lymphoma, and pediatric high-grade glioma.

2CLR 125 (CLR 121125)
CategoryTargeted Radiopharmaceutical Therapy
Description

Iodine-125 Auger-emitting PDC program targeting solid tumors including triple-negative breast cancer, lung, and colorectal cancer; currently in a Phase 1b dose-finding study in TNBC to determine the recommended dose for a subsequent Phase 2 trial.

3CLR 225 (CLR 121225)
CategoryTargeted Radiopharmaceutical Therapy
Description

Actinium-225 based alpha-emitting PDC program targeting solid tumors with high unmet need such as pancreatic cancer; has shown activity in multiple solid tumor animal models including pancreatic, colorectal, and breast cancers.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeOthersAnnounced on2025-12-01
Description

Multi-year supply agreement for Actinium-225 and Astatine-211 radioisotopes. Ionetix provides reliable supply of alpha-emitting radioisotopes critical for the company's CLR 125 and future alpha-particle therapy programs using the PDC platform.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Commercial-stage radiopharmaceutical company developing targeted radiation therapies and imaging agents for oncology, including prostate cancer (Illuccix) and other solid tumors. Closest direct comparable given similar PDC/radioconjugate approach and clinical-stage pipeline.

TypeBroad incumbent
Description

Established radiopharmaceutical company with commercial portfolio including diagnostic imaging agents (e.g., DEFINITY, Neuraceq) and therapeutic radiopharmaceuticals (PNT2002). Larger incumbent serving overlapping oncology radiopharmacy channels.

TypeBroad incumbent
Description

Major pharma with Pluvicto (lutetium-177 PSMA-617) and Lutathera radioligand therapies for prostate cancer and neuroendocrine tumors. Sets the commercial benchmark and competitive context for targeted radiopharmaceutical therapies.

TypeBroad incumbent
Description

Developer of Xofigo (radium-223) for metastatic castration-resistant prostate cancer and active investor/developer in radiopharmaceuticals through acquisitions including Algeta and Noria Therapeutics.

5Bristol-Myers Squibb
TypeBroad incumbent
Description

Major oncology company with RayzeBio acquisition ($4.1B) bringing actinium-225 based radiopharmaceutical platform targeting solid tumors. Represents a key strategic competitor in alpha-emitter oncology space.

TypeBroad incumbent
Description

Acquired POINT Biopharma for $1.4B in late 2023, adding a pipeline of radioligand therapies including PNT2002 for prostate cancer. Active participant in commercial-stage radiopharmaceutical market development.

TypeEmerging player
Description

Clinical-stage biotech developing targeted alpha therapies using actinium-225 conjugates for solid tumors (acquired by AstraZeneca in 2024 for $2.4B). Direct comparable in alpha-emitter oncology development approach.

TypeEmerging player
Description

European radiopharmaceutical company developing therapeutic and diagnostic radionuclides including Lu-177, Ac-225, and Y-90 based targeted therapies. Comparable platform approach targeting oncology indications.

TypeEmerging player
Description

Private clinical-stage radiopharmaceutical company developing targeted radionuclide therapies for cancers including SSTR2-expressing tumors. Compares to Cellectar as a similarly staged targeted radionuclide company.

TypeBroad incumbent
Description

Major oncology company that acquired Fusion Pharmaceuticals in 2024 for actinium-225 based alpha-emitter radioconjugate platform. Active strategic entrant into targeted radiopharmaceutical oncology space.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds16 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors17 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cellectar Biosciences

Targeted Radiopharmaceutical Cancer Therapiescellectar.com

Cellectar Biosciences is a late-stage clinical biopharmaceutical company developing targeted radiopharmaceutical cancer therapies using its proprietary Phospholipid Drug Conjugate (PDC) platform, with lead asset Iopofosine I 131 advancing toward FDA accelerated approval in Waldenström Macroglobulinemia.

What Cellectar Biosciences does

Cellectar Biosciences, Inc. (NASDAQ: CLRB) is a late-stage clinical biopharmaceutical company founded in 2002 and headquartered in Florham Park, New Jersey, that develops targeted radiopharmaceutical cancer therapies using its proprietary Phospholipid Drug Conjugate (PDC) platform. The PDC platform exploits lipid raft microdomains in tumor cell plasma membranes to selectively deliver radioisotope and cytotoxic payloads to cancer cells while sparing healthy tissue, and supports multiple emission modalities — beta (I-131), Auger (I-125), and alpha (Ac-225) — from a single targeting chassis.

The company's lead product candidate is Iopofosine I 131 (CLR 131), a first-in-class PDC delivering iodine-131, which is advancing toward an FDA accelerated approval filing in relapsed/refractory Waldenström Macroglobulinemia (WM). Updated 12-month Phase 2b CLOVER WaM data showed an 83.6% overall response rate and 61.8% major response rate in WM patients. Iopofosine has accumulated Breakthrough Therapy, six Orphan Drug, two Fast Track, and four Rare Pediatric Disease designations from the FDA, plus EMA PRIME and Orphan Drug designations and Conditional Marketing Authorization feedback for the EU. The pipeline additionally includes CLR 125 (Auger-emitting, Phase 1b in triple-negative breast cancer) and CLR 225 (alpha-emitting actinium-225 program with preclinical activity in pancreatic and other solid tumors), both leveraging the same PDC delivery chassis.

Cellectar is pre-revenue with no commercialized products. Its business model depends on securing regulatory approval and then distributing iopofosine directly to hospitals and cancer treatment centers with radiopharmacy capabilities, supplemented today by NCI/NIH grant funding and recurring equity financings. The most recent capital event is the May 2026 oversubscribed financing of up to $140 million led by Nantahala Capital, intended to fund a confirmatory Phase 3 study in WM and an FDA accelerated approval filing. As of March 31, 2026, the company held approximately $8.3 million in cash and reported an accumulated deficit of $274.9 million as of December 31, 2025, with operating losses reflecting ongoing clinical development rather than commercial activity.

Cellectar Biosciences firmographics

Firmographics
Name
Cellectar Biosciences
Legal name
Cellectar Biosciences, Inc.
Website
https://cellectar.com
Company type
Public
Founded year
2002
Operating status
Operating
Headcount range
11–50 employees
Short description
Cellectar Biosciences is a late-stage clinical biopharmaceutical company developing targeted radiopharmaceutical cancer therapies using its proprietary Phospholipid Drug Conjugate (PDC) platform, with lead asset Iopofosine I 131 advancing toward FDA accelerated approval in Waldenström Macroglobulinemia.
Ownership category
akta.pro rank

Cellectar Biosciences industry classification

Industry
Product category
Targeted Radiopharmaceutical Cancer Therapies
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAC
Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine

Keywords

  • Targeted cancer therapy
  • Phospholipid drug conjugates
  • Radiopharmaceutical oncology
  • Hematologic cancer treatment
  • Clinical stage biopharmaceuticals

Where Cellectar Biosciences is headquartered

Location

Headquarters

HQ city
Florham Park
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Cellectar Biosciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Product Sales (Future): Once regulatory approvals are obtained, the company plans to generate revenue through direct sales of iopofosine I 131 and future PDC-based therapeutics to hospitals, cancer treatment centers, and specialty pharmacies. Revenue model will involve specialty pharmaceutical distribution with hospital/health system contracting.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Cellectar Biosciences product offering

Product offering

Core offering

Cellectar Biosciences is a late-stage clinical biopharmaceutical company developing targeted radiopharmaceutical cancer therapies built on its proprietary Phospholipid Drug Conjugate (PDC) platform. Its lead clinical asset, Iopofosine I 131, delivers iodine-131 selectively to cancer cells via lipid raft targeting, with ongoing Phase 2b/Phase 3 programs in Waldenström Macroglobulinemia, multiple myeloma, CNS lymphoma, and pediatric high-grade glioma, plus earlier-stage Auger- and alpha-emitting PDC candidates for solid tumors.

Product overview

Cellectar Biosciences is a late-stage clinical biopharmaceutical company developing a portfolio of targeted cancer therapies using its proprietary Phospholipid Drug Conjugate (PDC) platform. The company's lead product is Iopofosine I 131, a first-in-class beta-emitting radioconjugate for treating relapsed or refractory Waldenström Macroglobulinemia and other hematologic cancers. The pipeline includes CLR 125 (iodine-125 Auger-emitting program for solid tumors) and CLR 225 (actinium-225 alpha-emitting program), both leveraging the PDC platform to selectively deliver radioisotopes to cancer cells while minimizing off-target effects.

Differentiator

Problem solved

Functional benefit

Products and services

  • Iopofosine I 131 (CLR 131) First-in-class Phospholipid Drug Conjugate delivering iodine-131 radioisotope selectively to cancer cells via lipid raft targeting; in development for relapsed/refractory Waldenström Macroglobulinemia, multiple myeloma, CNS lymphoma, and pediatric high-grade glioma.
  • CLR 125 (CLR 121125) Iodine-125 Auger-emitting PDC program targeting solid tumors including triple-negative breast cancer, lung, and colorectal cancer; currently in a Phase 1b dose-finding study in TNBC to determine the recommended dose for a subsequent Phase 2 trial.
  • CLR 225 (CLR 121225) Actinium-225 based alpha-emitting PDC program targeting solid tumors with high unmet need such as pancreatic cancer; has shown activity in multiple solid tumor animal models including pancreatic, colorectal, and breast cancers.

Quantifiable outcome

  • Objective response rate data from CLOVER trial pending completion
  • +1 more outcomes

Companies that use Cellectar Biosciences

Customer profile

Named customers4 records

Segments2 records

Ideal customer profiles2 records

Cellectar Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Cellectar Biosciences partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Ionetix CorporationcoreOthers · 1 December 2025Multi-year supply agreement for Actinium-225 and Astatine-211 radioisotopes. Ionetix provides reliable supply of alpha-emitting radioisotopes critical for the company's CLR 125 and future alpha-particle therapy programs using the PDC platform.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Cellectar Biosciences competitors and assessment

Company assessment

Direct peers

  • Telix Pharmaceuticals: Commercial-stage radiopharmaceutical company developing targeted radiation therapies and imaging agents for oncology, including prostate cancer (Illuccix) and other solid tumors. Closest direct comparable given similar PDC/radioconjugate approach and clinical-stage pipeline.

Broad incumbents

  • Lantheus Holdings: Established radiopharmaceutical company with commercial portfolio including diagnostic imaging agents (e.g., DEFINITY, Neuraceq) and therapeutic radiopharmaceuticals (PNT2002). Larger incumbent serving overlapping oncology radiopharmacy channels.
  • Novartis: Major pharma with Pluvicto (lutetium-177 PSMA-617) and Lutathera radioligand therapies for prostate cancer and neuroendocrine tumors. Sets the commercial benchmark and competitive context for targeted radiopharmaceutical therapies.
  • Bayer: Developer of Xofigo (radium-223) for metastatic castration-resistant prostate cancer and active investor/developer in radiopharmaceuticals through acquisitions including Algeta and Noria Therapeutics.
  • Bristol-Myers Squibb: Major oncology company with RayzeBio acquisition ($4.1B) bringing actinium-225 based radiopharmaceutical platform targeting solid tumors. Represents a key strategic competitor in alpha-emitter oncology space.
  • Eli Lilly: Acquired POINT Biopharma for $1.4B in late 2023, adding a pipeline of radioligand therapies including PNT2002 for prostate cancer. Active participant in commercial-stage radiopharmaceutical market development.
  • AstraZeneca: Major oncology company that acquired Fusion Pharmaceuticals in 2024 for actinium-225 based alpha-emitter radioconjugate platform. Active strategic entrant into targeted radiopharmaceutical oncology space.

Emerging players

  • Fusion Pharmaceuticals: Clinical-stage biotech developing targeted alpha therapies using actinium-225 conjugates for solid tumors (acquired by AstraZeneca in 2024 for $2.4B). Direct comparable in alpha-emitter oncology development approach.
  • ITM Isotope Technologies: European radiopharmaceutical company developing therapeutic and diagnostic radionuclides including Lu-177, Ac-225, and Y-90 based targeted therapies. Comparable platform approach targeting oncology indications.
  • Ariceum Therapeutics: Private clinical-stage radiopharmaceutical company developing targeted radionuclide therapies for cancers including SSTR2-expressing tumors. Compares to Cellectar as a similarly staged targeted radionuclide company.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Cellectar Biosciences social profiles

Digital presence

Cellectar Biosciences compliance and trust

Trust signal

Compliance5 records

Cellectar Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cellectar Biosciences leadership team

Management profile

Number of profiles

Profiles9 records

Cellectar Biosciences funding detail

Funding detail

Funding overview

Funding rounds16 records

Investors17 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cellectar Biosciences M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cellectar Biosciences

What does Cellectar Biosciences do?

Cellectar Biosciences is a late-stage clinical biopharmaceutical company developing targeted radiopharmaceutical cancer therapies built on its proprietary Phospholipid Drug Conjugate (PDC) platform. Its lead clinical asset, Iopofosine I 131, delivers iodine-131 selectively to cancer cells via lipid raft targeting, with ongoing Phase 2b/Phase 3 programs in Waldenström Macroglobulinemia, multiple myeloma, CNS lymphoma, and pediatric high-grade glioma, plus earlier-stage Auger- and alpha-emitting PDC candidates for solid tumors.

Is Cellectar Biosciences a public or private company?

Cellectar Biosciences is a public company. It is classified as public and is currently operating.

When was Cellectar Biosciences founded?

Cellectar Biosciences was founded in 2002. It employs 11 to 50 people.

Where is Cellectar Biosciences based?

Cellectar Biosciences is headquartered in Florham Park, United States, in the North America region.

How does Cellectar Biosciences make money?

One revenue line is on record: pharmaceutical Product Sales (Future).

Who are Cellectar Biosciences's main competitors?

Telix Pharmaceuticals is listed as a direct peer. Broad incumbents are Lantheus Holdings, Novartis, Bayer, Bristol-Myers Squibb, Eli Lilly and AstraZeneca. Emerging players are Fusion Pharmaceuticals, ITM Isotope Technologies and Ariceum Therapeutics.

Does Cellectar Biosciences have an API?

No public API is recorded for Cellectar Biosciences.

What industry is Cellectar Biosciences in?

Cellectar Biosciences's product category is Targeted Radiopharmaceutical Cancer Therapies. Its primary akta.pro industry code is HLAIAGAB, Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy), with a secondary code of HLAIAGAC, Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx). Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BenzingaCellectar Biosciences Q3 2026 Earnings Call Transcript - Cellectar Biosciences (NASDAQ:CLRB)Cellectar Biosciences reported Q3 2026 cash of $24.6 million, up from $13.2 million, after a $140 million financing. The company initiated its confirmatory Phase 3 trial for iopofosine I-131 in Waldenstrom's macroglobulinemia, with first patient dosing expected in Q1 2027 and an NDA submission targeted for H1 2027. Potential commercial availability is projected for late 2027 or early 2028.The future of tradingCellectar Biosciences Q3 net loss widens on higher R&D costsCellectar Biosciences reported a Q3 net loss of $8 million, widening year-over-year on higher R&D costs from Phase 3 trial preparations and ongoing CLR 125 activity. The company expects cash to fund operations into Q2 2027 and plans to file for accelerated FDA approval for iopofosine I 131 in the first half of 2027.Quiver QuantitativeCellectar Biosciences Reports Q3 2026 Results, Highlights Iopofosine I 131 Data Supporting WM Accelerated Approval Pathway | CLRB Stock NewsCellectar Biosciences reported Q3 2026 results, including a net loss of $8 million and an overall response rate of 87.5% for iopofosine I 131 in Waldenström macroglobulinemia. The company plans to start Phase 3 dosing in Q1 2027 and submit an FDA accelerated approval NDA in H1 2027.The future of tradingCellectar BioSciences Q3 net loss widens 79% to $7.97 millionCellectar BioSciences reported a Q3 2026 net loss of $7.97 million, up 79% year over year, with R&D expenses of $5.44 million. Cash on hand was $24.58 million, and first patients in the confirmatory Phase 3 trial of iopofosine I 131 are scheduled for dosing in early 2027, with an FDA application planned for the first half of 2027.American Banking and Market NewsCellectar Biosciences (CLRB) Expected to Announce Quarterly Earnings on TuesdayCellectar Biosciences is expected to report Q3 2026 earnings on Tuesday, November 10th, with analysts projecting a loss of $0.5565 per share and revenue of $17.00 million. The stock opened at $1.25, and analysts have a consensus rating of Moderate Buy with a target price of $11.00.Business & FinancialCellectar Biosciences To Report Third Quarter Financial Results And Host A Conference Call On Tuesday, November 10, 2026Cellectar Biosciences will report its third-quarter financial results and host a conference call on Tuesday, November 10, 2026, at 8:30 am Eastern Time. The company's pipeline includes iopofosine I-131 and CLR 125, with Phase 2b trials and a Phase 1b study in pediatric gliomas.The future of tradingCellectar BioSciences Presents Phase 3 Trial Plan for Iopofosine in Waldenström MacroglobulinemiaCellectar BioSciences plans to submit an FDA accelerated approval application for iopofosine I 131 in Waldenström macroglobulinemia in the first half of 2027, with potential US approval in the second half. The Phase 3 trial targets about 200 patients, with first enrollment in Q1 2027 and an estimated cost of $42 million.American Banking and Market NewsCellectar Biosciences, Inc. (CLRB) – What Are Analysts Saying About This Stock?Analysts give Cellectar Biosciences an average 'Moderate Buy' rating with a $11.00 price target. The stock opened at $1.21, and the company reported Q2 EPS of -$0.57, missing the -$0.52 consensus. Analysts expect -$2.39 EPS for the current year.Markets DailyCellectar Biosciences, Inc. (NASDAQ:CLRB) Stock Has Consensus Target Price of $11.00Cellectar Biosciences received an average 'Moderate Buy' rating from five analysts, with a $11.00 price target. The stock opened at $1.28, and the company missed Q2 EPS estimates at -$0.57 versus -$0.52 expected. Analysts project a fiscal-year EPS of -$2.39.Investing.comCellectar reports trial data for cancer drug in rare diseaseCellectar Biosciences presented Phase 2b trial data for iopofosine I 131 in Waldenström macroglobulinemia, showing an 87.5% overall response rate and 100% clinical benefit in 24 patients. The company plans a Phase 3 confirmatory trial with first patients in Q1 2027 and expects an FDA accelerated approval application in H1 2027.